NASDAQ$VYNE
VYNE Therapeutics INC · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
VYNE Therapeutics reported sharply lower operating expenses and a narrower net loss for the first quarter ended March 31, 2026.
The company recorded royalty revenue of $86,000 while reducing total operating expenses to $3.9 million from $9.4 million in the prior-year quarter. Net loss narrowed to $3.6 million, or $0.08 per share, supported by a cash position of $24.6 million at quarter end. Management continued to advance the proposed merger with Yarrow Biosciences while winding down internal R&D activities.
- Royalty revenue declined to $86,000 from $202,000 year-over-year as the company focuses on the pending merger.
- Research and development expenses fell 87% to $817,000 following termination of the repibresib and VYN202 clinical trials.
- Cash, cash equivalents and marketable securities totaled $24.9 million, providing runway through the anticipated merger closing.
- Weighted-average shares outstanding were 42.8 million; the company plans a special cash dividend of $14.5-$16.5 million prior to merger close.
Headline financials
Revenue & EPS history
VYNE · Revenue · Quarterly
$86K
Revenue by segment
VYNE · $86K total across 1 segment · Q1 2026
- Royalty revenues$86K—100.0%
Forward guidance
The company expects to complete the merger with Yarrow Biosciences in the third quarter of 2026 and will declare a special cash dividend of approximately $14.5-$16.5 million prior to closing.
Tailwinds
- Cash runway sufficient through merger closing and for at least 12 months thereafter.
- Significant reduction in quarterly cash burn following R&D wind-down.
Headwinds
- No product revenue expected post-merger; royalties from Finacea represent passive income only.
- Merger completion remains subject to stockholder and regulatory approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-1.0%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-13.3%
Avg return
30 days after
52%
17 / 33 earnings
Positive
+23.0%
Q4 2021
Best reaction
-38.4%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | — | — | |
| Q4 2025 | +1.0% | -0.2% | -0.5% | |
| Q2 2025 | +0.6% | -4.3% | -10.6% | |
| Q1 2025 | -2.4% | -20.0% | -28.1% | |
| Q4 2024 | -2.5% | -21.3% | -34.7% | |
| Q3 2024 | +1.0% | -4.2% | -14.4% | |
| Q2 2024 | +8.8% | +8.2% | +7.6% | |
| Q1 2024 | -1.8% | +6.3% | -17.3% | |
| Q4 2023 | -4.7% | -3.4% | +31.8% | |
| Q3 2023 | +1.7% | +11.4% | -23.1% | |
| Q2 2023 | -11.8% | -13.7% | -26.7% | |
| Q1 2023 | +20.9% | +17.9% | -11.9% | |
| Q4 2022 | -14.7% | -21.2% | -11.1% | |
| Q3 2022 | +9.7% | +0.0% | -15.4% | |
| Q2 2022 | +5.3% | +12.5% | -4.6% | |
| Q1 2022 | +5.0% | +8.2% | +27.2% | |
| Q4 2021 | +23.0% | +28.7% | -8.0% | |
| Q3 2021 | -1.5% | -5.9% | +10.3% | |
| Q2 2021 | -38.4% | -42.9% | -45.7% | |
| Q1 2021 | -19.7% | -24.8% | -95.3% | |
| Q4 2020 | -9.7% | -6.5% | -6.5% | |
| Q3 2020 | -2.6% | +0.6% | -1.2% | |
| Q2 2020 | -12.5% | -12.2% | -26.8% | |
| Q1 2020 | -7.2% | -13.3% | +7.2% | |
| Q4 2019 | +5.8% | +42.6% | -9.3% | |
| Q3 2019 | +4.4% | +2.6% | -21.3% | |
| Q2 2019 | -8.7% | -16.4% | +29.8% | |
| Q1 2019 | -1.3% | -2.3% | -4.5% | |
| Q4 2018 | +0.5% | +0.2% | -7.3% | |
| Q3 2018 | +1.7% | +0.0% | -17.8% | |
| Q2 2018 | +3.4% | -2.7% | -5.9% | |
| Q1 2018 | +9.2% | +7.2% | -11.9% | |
| Q4 2017 | +4.8% | +2.9% | -78.1% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro